JP2023522029A - イヌ科動物抗体バリアント - Google Patents

イヌ科動物抗体バリアント Download PDF

Info

Publication number
JP2023522029A
JP2023522029A JP2022562645A JP2022562645A JP2023522029A JP 2023522029 A JP2023522029 A JP 2023522029A JP 2022562645 A JP2022562645 A JP 2022562645A JP 2022562645 A JP2022562645 A JP 2022562645A JP 2023522029 A JP2023522029 A JP 2023522029A
Authority
JP
Japan
Prior art keywords
antibody
igg
constant domain
canine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522029A5 (https=
JPWO2021212081A5 (https=
Inventor
バージェロン，リサ・マリー
カンポス，ヘンリー・ルイス
Original Assignee
ゾエティス・サービシーズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾエティス・サービシーズ・エルエルシー filed Critical ゾエティス・サービシーズ・エルエルシー
Publication of JP2023522029A publication Critical patent/JP2023522029A/ja
Publication of JP2023522029A5 publication Critical patent/JP2023522029A5/ja
Publication of JPWO2021212081A5 publication Critical patent/JPWO2021212081A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022562645A 2020-04-17 2021-04-16 イヌ科動物抗体バリアント Pending JP2023522029A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011453P 2020-04-17 2020-04-17
US63/011,453 2020-04-17
PCT/US2021/027836 WO2021212081A1 (en) 2020-04-17 2021-04-16 Canine antibody variants

Publications (3)

Publication Number Publication Date
JP2023522029A true JP2023522029A (ja) 2023-05-26
JP2023522029A5 JP2023522029A5 (https=) 2024-04-19
JPWO2021212081A5 JPWO2021212081A5 (https=) 2024-04-19

Family

ID=75888187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562645A Pending JP2023522029A (ja) 2020-04-17 2021-04-16 イヌ科動物抗体バリアント

Country Status (17)

Country Link
US (1) US20230242635A1 (https=)
EP (1) EP4136106A1 (https=)
JP (1) JP2023522029A (https=)
KR (1) KR20230005156A (https=)
CN (1) CN115996949A (https=)
AU (1) AU2021256056A1 (https=)
BR (1) BR112022020944A2 (https=)
CA (1) CA3175921A1 (https=)
CL (2) CL2022002857A1 (https=)
CO (1) CO2022014695A2 (https=)
EC (1) ECSP22080846A (https=)
IL (1) IL297287A (https=)
MX (1) MX2022012866A (https=)
PE (1) PE20230108A1 (https=)
PH (1) PH12022552742A1 (https=)
TW (1) TW202204403A (https=)
WO (1) WO2021212081A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
US11542333B2 (en) 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US11434276B2 (en) 2020-05-11 2022-09-06 Invetx, Inc. Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
EP4178977A1 (en) 2020-07-10 2023-05-17 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
IL301413A (en) * 2020-09-28 2023-05-01 Zoetis Services Llc Canine antibody variants
KR20250026186A (ko) * 2022-06-21 2025-02-25 조에티스 서비시즈 엘엘씨 갯과 항체 돌연변이체
JP2026508096A (ja) 2023-01-20 2026-03-10 ゾエティス・サービシーズ・ユーケー・リミテッド 治療抗体
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014529295A (ja) * 2011-07-21 2014-11-06 ゾエティス・エルエルシー インターロイキン−３１モノクローナル抗体
JP2015521461A (ja) * 2012-06-06 2015-07-30 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
JP2017536800A (ja) * 2015-09-18 2017-12-14 中外製薬株式会社 Ｉｌ−８に結合する抗体およびその使用
WO2018025982A1 (ja) * 2016-08-05 2018-02-08 中外製薬株式会社 Ｉｌ－８関連疾患の治療用又は予防用組成物
JP2018510842A (ja) * 2015-02-05 2018-04-19 中外製薬株式会社 イオン濃度依存的抗原結合ドメインを含む抗体、Ｆｃ領域改変体、ＩＬ−８に結合する抗体、およびその使用
JP2022504868A (ja) * 2018-10-18 2022-01-13 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための、新生仔ｆｃ受容体（ｆｃｒｎ）への結合性が変化したｆｃ変異体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
RS61723B1 (sr) * 2011-02-04 2021-05-31 Zoetis Services Llc Imunogenične bordetella bronchiseptica kompozicije
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
WO2018073185A1 (en) * 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
WO2018156180A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US11542333B2 (en) * 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US20220169740A1 (en) * 2019-03-20 2022-06-02 Kindred Biosciences, Inc. NGF Antagonists for Medical Use
IL301413A (en) * 2020-09-28 2023-05-01 Zoetis Services Llc Canine antibody variants
WO2022165067A2 (en) * 2021-01-28 2022-08-04 Zoetis Services Llc Mutations in canine antibody constant regions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014529295A (ja) * 2011-07-21 2014-11-06 ゾエティス・エルエルシー インターロイキン−３１モノクローナル抗体
JP2015521461A (ja) * 2012-06-06 2015-07-30 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
JP2018510842A (ja) * 2015-02-05 2018-04-19 中外製薬株式会社 イオン濃度依存的抗原結合ドメインを含む抗体、Ｆｃ領域改変体、ＩＬ−８に結合する抗体、およびその使用
JP2017536800A (ja) * 2015-09-18 2017-12-14 中外製薬株式会社 Ｉｌ−８に結合する抗体およびその使用
WO2018025982A1 (ja) * 2016-08-05 2018-02-08 中外製薬株式会社 Ｉｌ－８関連疾患の治療用又は予防用組成物
JP2022504868A (ja) * 2018-10-18 2022-01-13 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための、新生仔ｆｃ受容体（ｆｃｒｎ）への結合性が変化したｆｃ変異体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DENG, R., ET AL.: ""Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mi", MABS, vol. 4, no. 1, JPN6025045372, 1 January 2012 (2012-01-01), pages 101 - 109, ISSN: 0005726111 *
NG, C.M., ET AL.: ""Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-thera", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 51, JPN6025012509, 2014, pages 51 - 58, ISSN: 0005726109 *
ZHENG, Y., ET AL.: ""Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody", CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 89, no. 2, JPN6025012510, 2011, pages 283 - 290, ISSN: 0005726110 *

Also Published As

Publication number Publication date
MX2022012866A (es) 2022-11-08
US20230242635A1 (en) 2023-08-03
TW202204403A (zh) 2022-02-01
ECSP22080846A (es) 2023-02-28
KR20230005156A (ko) 2023-01-09
CA3175921A1 (en) 2021-10-21
WO2021212081A1 (en) 2021-10-21
AU2021256056A1 (en) 2022-10-20
PE20230108A1 (es) 2023-01-25
PH12022552742A1 (en) 2024-03-25
IL297287A (en) 2022-12-01
EP4136106A1 (en) 2023-02-22
BR112022020944A2 (pt) 2022-12-27
CL2023003377A1 (es) 2024-04-19
CN115996949A (zh) 2023-04-21
CO2022014695A2 (es) 2022-10-21
CL2022002857A1 (es) 2023-06-02

Similar Documents

Publication Publication Date Title
JP2023522029A (ja) イヌ科動物抗体バリアント
US20250026834A1 (en) Feline antibody variants
JP2024503212A (ja) ネコ科動物抗体の定常領域における変異
JP2023543262A (ja) イヌ科動物抗体バリアント
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
TWI880316B (zh) 貓抗體變異體
US12612454B2 (en) Canine antibody variants
RU2840969C1 (ru) Варианты кошачьих антител
US12612455B2 (en) Feline antibody variants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240409

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260319